Mizuho Maintains Outperform on CVS Health, Lowers Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Ann Hynes maintains an Outperform rating on CVS Health but lowers the price target from $73 to $66.

October 24, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho analyst Ann Hynes maintains an Outperform rating on CVS Health but lowers the price target from $73 to $66.
The Outperform rating suggests continued confidence in CVS Health's performance, but the lowered price target indicates some caution about future growth. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100